**Original Research Article**

**Efficacy of a polyherbal formulation in the management of benign prostatic hyperplasia: a randomized, controlled trial**

Shabir Ahmad Bhat*, Shameem Ahmad Rather, Naquibul Islam

Department of Moalajat, Regional Research Institute of Unani Medicine, Naseembagh, University of Kashmir, Srinagar, Jammu and Kashmir, India

Received: 04 July 2021  
Accepted: 04 August 2021

*Correspondence:  
Shabir Ahmad Bhat,  
E-mail: drshabirbhat11.sb@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**ABSTRACT**

**Background:** Benign prostatic hyperplasia (BPH) affects a significant number of men beyond the age of 40 years with its incidence reaching up to 90% in 80’s. Despite multiple treatment innovations, BPH still remains a nightmare for ageing men, mostly due to its distressing lower urinary tract symptoms (LUTS) and sexual dysfunction. The severity of LUTS is graded by international prostate symptom score or American urological association symptom index (AUA-SI) along with impact on quality of life (QOL). The objective of this study was to evaluate the efficacy of an Unani polyherbal formulation, Habb-i-muqil, in improving the AUA-SI and QOL in patients with BPH.

**Methods:** In an open, standard controlled study, 76 men, diagnosed with clinical BPH, aged between 40 and 80 years were randomly allocated for treatment for duration of 90 days with Habb-i-muqil (test drug) or Tamsulosin (standard control) after ethical approval. AUA-SI and QOL were assessed at baseline (0 day) and days 15, 30, 45, 60, 75 and 90.

**Results:** Analysis of 60 men showed that after 90 days of treatment the percentage changes in the AUA-SI from baseline were 59.4 and 49.4% by Habb-i-muqil and tamsulosin, respectively. The test drug produced statistically significant improvement (p<0.001) in overall AUA-SI and QOL compared with standard control.

**Conclusions:** The Unani polyherbal formulation, Habb-i-muqil, was effective in improving AUA-SI and QOL in men with BPH in comparison to tamsulosin. Both the treatments were generally well tolerated.

**Keywords:** Benign prostatic hyperplasia, LUTS, Habb-i-muqil, Quality of life

**INTRODUCTION**

Benign prostatic hyperplasia (henceforth BPH) is one of the commonest non-malignant neoplasms to affect men beyond middle age.¹ The incidence of BPH increase with age so that it affects approximately 20% of men in their 40s reaching up to 90% in 9th decade.² Despite multiple treatment innovations, BPH still remains a nightmare for the ageing men, mostly due to its distressing lower urinary tract symptoms (LUTS) affecting quality of life (QOL) and sexual functions.³ Dihydrotestosterone (DHT) derived from testosterone through the action of 5-alpha reductase seems to be the major stimulus for proliferation of prostate in men with nodular hyperplasia.⁴ Inflammatory mediators and local growth factors are also considered to be responsible for prostatic hyperplasia.⁵ Moreover, inheritance, metabolic syndrome, obesity and decreased physical activity increase the risk factors of prostatic hyperplasia.⁶ Unani, an age-old traditional system of medicine, which is based on the ‘humoral theory’ proposed by Hippocrates (480-370 BC), the father of medicine, states that any disturbance in the ratio of four humors is responsible for the disease. One of the major humors to which our hormones also belong is phlegm (Balgham).⁷ So, according to this very system of medicine...
BPH is a phlegmatic disorder caused by derangement of phlegm, a cold humor.\textsuperscript{10}

For evaluating suspected BPH patients, American Urologic Association, European Association of Urology and “WHO international consultation on urologic disease” has recommended the routine use of International prostatic symptom score (IPSS).\textsuperscript{11,12}

Most commonly used class of drug for treating bothersome LUTS in BPH is α-adrenergic receptor antagonist and selective α1-receptor blocker. Although these are effective in alleviating bothersome LUTS, they have various side effects like, dizziness, fatigue, asthenia, postural hypotension and ejaculatory disturbances.\textsuperscript{13}

In Unani system of medicine natural herbs which are comparatively safer have been in use for centuries in alleviating urinary symptoms. These herbs, however, need to be evaluated on scientific parameters. To avoid the side effects of conventional medicine, a study was conducted to evaluate the efficacy of a polyherbal formulation, Habb-i-muqil, in the treatment of LUTS due to BPH.

Habb-i-muqil was selected for this study because of its following properties; it is deobstruent, anti-inflammatory, anti-tumor, phlemagogue, laxative and aphrodisiac.\textsuperscript{14-16} Commiphora mukul, one of its major ingredients, is effective in urinary disorders and is also a potent androgen receptor antagonist and estrogen receptor agonist.\textsuperscript{17,18} Guggulsterone and gallic acid, like constituents in it are considered as ideal chemopreventive, apoptotic and robust therapeutic agents for prostate cancer.\textsuperscript{19,20}

\section*{Methods}

An open, randomized, standard controlled trial was conducted from December 2018 to December 2019 at Regional Research Institute of Unani Medicine, Srinagar Kashmir, after gaining approval on 09-12-2017 from institutional ethical committee (Regional Research Institute of Unani Medicine, Central Council for Research in Unani Medicine, Ministry of Ayush Government of India). A written informed consent was obtained from all the participating patients. Diagnosis and selection of the cases was made on the basis of clinical features, American Urological Association-Symptom index (IPSS) (AUA-SI), QOL, ultra-sonography (USG) per abdomen for prostate volume and serum prostate specific antigen (PSA) along with other safety parameters [LFT, KFT, CBC, ESR, blood sugar, ECG, and X-ray (KUB)].

\section*{Case selection criteria}

\subsection*{Inclusion criteria}

Males in age group of 40-80 years complaining of LUTS and clinically stable patients of BPH with serum PSA level <10 ng/ml were included.

\subsection*{Exclusion criteria}

Patients below 40 and above 80 years of age; with intellectual disability and who fail to give consent; with other debilitating diseases like CHD, CKD, liver disease and hypertension; and complete retention of urine and serum PSA ≥10 ng/ml.

\section*{Intervention}

Test drug formulation, Habb-i-muqil, consisting of following ingredients- (a) Commiphora mukul (Mukil) (85 g); (b) three different forms of Terminalia chebula (Halela Zard, Halela Siyā, Halela Kābli) (60 g each), Emblica officinalis (Āmila Khushk) (60 g), Ferula persica (Sakbīmaj) (20 g), Bressica nigra (Khardal) (10 g), all the ingredients were powdered and mixed with 20 ml sweet almond oil (Roghani-i-Bādām shirīn) and 100 ml Āb-i-Gandana, to make the pills of 250 mg.

1 g of it was given to the cases of test group twice a day orally with water, leaving a twelve hours gap between the two doses.

The other group that is the control group was given a standard conventional drug, tamsulosin, 0.4 mg in tablet form, only once a day orally, thus leaving a 24 hours gap between the two doses.

Both the drugs were continued for a period of 90 days in each patient after taking a written consent from them.

\section*{Assessment}

All the BPH patients having LUTS were assessed for AUA-SI and QOL at baseline (0 day) and days 15, 30, 45, 60, 75 and 90.

In addition to this prostate volume and PSA were assessed before initiation and after completion of the treatment. Various safety parameters were also checked before and after study to evaluate the safety of the test drug. The patients’ summary is given by consort flow diagram below in Figure 1.

\section*{Data analysis}

Data was entered in a spread sheet and then exported to data editor of SPSS version 20.0 and Graph pad prism software. The continuous variables were expressed as mean±SD and categorical variables were expressed in terms of frequency and percentage. Students’ independent t-test was employed for inter-group (test group vs. control group) analysis of data, and for intra-group analysis paired t-test was applied. Chi square test was employed for comparison of categorical variables. The graphical representation of data was presented by means of bar and line graphs. A p value of less than 0.05 was considered statistically significant.
RESULTS

Out of 76 randomly allocated patients only 60 were analyzed statistically for the results, 30 from each test group and control group. Distribution of patients as per their age in both the groups and total percentage of each age group thereafter is shown in the Table 1. Mean±SD of urinary symptoms before and after trial i.e.; at 0th day and at 90th day was calculated and the effect in both the groups was derived statistically as can be easily understood in Table 2.

Comparing the values of baseline and post treatment, the effect of test drug was seen highly significant (p<0.001) in the six parameters whereas less significant for ‘weak stream’ (p=0.007). Moreover, in comparison to standard drug the effect of test drug was highly significant (p<0.001) for ‘frequency of micturition’, ‘urgency’, ‘weak stream’ and ‘nocturia’, whereas it was less significant for ‘straining’ (p=0.0324) and insignificant for ‘incomplete emptying of bladder’ (p=0.869) and ‘intermittency’ (p=0.781).

Baseline values of mean±SD of AUA-SI and QOL in test group comparison to control group (17.16±4.99 vs 17.66±3.95) and (4.76±0.67 vs 4.93±0.58) improved after treatment to (6.96±2.87 vs 8.93±3.09) and (2.36±0.66 vs 3.06±0.58) respectively. Statistically effect of test drug formulation was found to be highly significant comparison to standard drug (p<0.001) with respect to AUA-SI and QOL (Table 3). Although the effect of the test drug in reducing prostate volume was not significant, but when compared with the control group the effect of the former was found to be significant (p<0.001) statistically. Contrarily, the effect on PSA was found to be insignificant (p=0.723) at 5% level of significance.
Table 1: Age distribution in test and control group.

| Age (years) | Test | Control | Total |
|-------------|------|---------|-------|
| N           | %    | N       | %     |
| 40-49       | 10   | 33.3    | 8     | 26.7 | 30 |
| 50-59       | 4    | 13.3    | 6     | 20.0 | 16.65 |
| 60-69       | 14   | 46.7    | 12    | 40.0 | 43.3 |
| 70-79       | 2    | 6.7     | 4     | 13.3 | 10 |
| Total       | 30   | 100     | 30    | 100  | 100 |

| Mean±SD     | 57.23±10.50 | 57.23±9.73 |

Table 2: Effect on urinary symptoms individually in test and control group.

| Groups                  | Test     | Control    | Test vs control (p value) |
|-------------------------|----------|------------|--------------------------|
| Incomplete emptying     | Before   | 3.33±1.18  | 3.46±1.18 | 0.869 |
| After                   | 1.17±0.69| 1.76±0.72  |             |       |
| Frequency               | Before   | 3.50±1.06  | 3.23±0.97 | <0.001* |
| After                   | 1.23±0.50| 1.86±0.57  |             |       |
| Intermittency           | Before   | 0.70±0.95  | 0.96±1.09 | 0.781  |
| After                   | 0.23±0.43| 0.40±0.67  |             |       |
| Urgency                 | Before   | 3.73±0.86  | 3.80±0.66 | <0.001* |
| After                   | 1.23±0.67| 2.16±0.59  |             |       |
| Weak stream             | Before   | 0.95±1.03  | 1.26±0.87 | <0.001* |
| After                   | 0.73±0.86| 0.40±0.60  |             |       |
| Straining               | Before   | 1.63±1.06  | 1.96±0.92 | 0.0324 |
| After                   | 0.82±0.64| 0.70±0.65  |             |       |
| Noctura                 | Before   | 3.33±0.80  | 2.96±0.80 | <0.001* |
| After                   | 1.00±0.58| 1.63±0.61  |             |       |

Table 3: Effect on AUA-SI and QOL in test and control group.

| Follow ups | AUA-SI (mean±SD) | QOL (mean±SD) | Test vs control (p value) |
|------------|------------------|---------------|--------------------------|
| Test       | Control          | Test          | Control                  |                           |
| 0 day (base line) | 17.16±4.99 | 17.66±3.95 | 4.76±0.67 | 4.93±0.58 | <0.001* |
| 15th day   | 16.33±4.97      | 15.83±3.53   | 4.66±0.71 | 4.60±0.67 |       |
| 30th day   | 13.10±4.23      | 12.16±3.15   | 3.83±0.64 | 3.80±0.55 |       |
| 45th day   | 12.10±4.11      | 11.46±3.31   | 3.66±0.71 | 3.73±0.58 |       |
| 60th day   | 8.90±3.11       | 9.56±2.84    | 3.03±0.49 | 3.26±0.58 |       |
| 75th day   | 8.43±2.97       | 9.30±2.89    | 2.86±0.57 | 3.06±0.58 |       |
| 90th day   | 6.96±2.87       | 8.93±3.09    | 2.36±0.66 | 2.90±0.60 |       |
| Percentage of improvement | 59.44 | 49.43 | 50.42 | 41.17 | <0.001* |
| P value    | <0.001*         | <0.001*      | <0.001*      | <0.001*      |       |

Note: AUA-SI- American Urological Association Symptom Index; QOL- Quality of life; SD- Standard deviation.

Table 4: Effect on prostate volume and PSA in test and control group.

| Groups | Prostate volume (Mean±SD) | PSA (Mean±SD) |
|--------|---------------------------|---------------|
|        | 0 day         | 90th day      | 0 day        | 90th day     |
| Test   | 34.73±15.02   | 29.64±13.01   | 1.08±1.08    | 0.96±0.93    |
| Control| 42.56±22.56   | 42.23±22.50   | 1.55±1.87    | 2.06±3.44    |
| P value| <0.001*       | 0.0723        |              |              |

Note: PSA- Prostate specific antigen; SD- Standard deviation.

**DISCUSSION**

In the treatment of symptomatic BPH physicians have given too much emphasis on International Prostatic Symptom Score (IPSS) (AUA-SI and QOL), prostate volume and urodynamic parameters. Subjective outcome measures are now widely used to assess treatment outcomes for LUTS and BPH. Among the conventional medicines alpha-1 adrenergic antagonist,
tamsulosin, is the most commonly recommended because of its tolerability, efficacy and safety.\textsuperscript{13} Herbal medicine, though in use for centuries in treating LUTS, is still lacking a comprehensive scientific validation except a few.\textsuperscript{23,24} However, some common side effects like loss of libido and retrograde ejaculation associated with the conventional medicine become strong factors for patients choosing herbal medicine.

Evaluating the safety and efficacy of the polyherbal formulation (Habb-i-muqil) in treating LUTS compared to the standard control (tamsulosin) was important in this context. This formulation so far has been evaluated to be effective for treating internal hemorrhoids (I and II), constipation, and osteo-arthritis.\textsuperscript{25,26} Most of its ingredients are having anti-tumor, anti-inflammatory, deobstruent, resolvent and aphrodisiac properties.\textsuperscript{27} This helps in effective urine outflow, reduce the volume of post void residual urine, decrease bladder irritation and lessen the frequent desire to micturate. Moreover, most of the ingredients in the test drug are hot in temperament according to the unani system of medicine which counteracts the effect of excess phlegm in the body and hence diminish the symptoms produced by it.\textsuperscript{14,27} \textit{Commiphora mukul}, one of its major ingredients acts as a potent androgen receptor antagonist and estrogen receptor agonist.\textsuperscript{18} It possesses anti-oxidant, apoptotic, anti-tumor and anti-cancerous property as well.\textsuperscript{19,20} Because inflammation and androgens are considered to be the main culprits for developing BPH, Habb-i-muqil was thought to be the best alternative for its management.\textsuperscript{28}

In the current randomized, standard controlled trial, 60 patients, who completed the trial duration as per the designed protocol, were analyzed (Figure 1). The mean age of the study group was 56.24±10.11 and maximum numbers of patients belonged to the age group of 60-69 years (Table 1). However, the data depicts least number of patients in the age group of 70-79 years which contradicts the concept of Baltimore and Krimpen longitudinal study of aging suggesting an increase in prostate volume with age.\textsuperscript{29,30} This contradiction is most probably due to the patients’ ineligibility as per the inclusion and exclusion criteria for the present study. Since most of the elderly patients having other associated ailments were excluded at the initial assessment.

To achieve ‘very satisfied’ or ‘satisfied’ response, a man with very severe symptoms (baseline IPSS 30) would require an improvement of almost 18 points, while a man with moderate symptoms (baseline IPSS 12) would require an improvement of 4 points as reported by Reohrborn et al.\textsuperscript{31} Barry et al evaluated a change of AUA symptom index of -8.8, -5.5, -3.0 and -0.7 points depicting marked, moderate, slight or no improvement respectively.\textsuperscript{32} However, in many clinical studies greater symptom index changes were associated with higher baseline score.\textsuperscript{31} Our study also showed similar tendencies (Table 3). The mean and standard deviation of all the seven subjective parameters most of whom showed significant improvement after treatment with the test drug formulation is illustrated in Table 2. Clearly, the test drug has improved the urgency of urine, its frequency and nocturia to a greater extent. Similarly, ‘straining’ showed a good improvement but at slower pace so that initially the improvement could be found more with control drug, whereas the test drug showed delayed but better results.

Overall AUA-SI (Table 3) got improved in both the test group and control group as 59.4% and 49.4% from the base line respectively. However, the inter-group comparison, test group vs control group (6.96±2.87 vs 8.93±3.09), depicted comparatively better effects of test intervention and was statistically found highly significant (p<0.001). Figure 2 portrays the improvement of AUA-SI in test group which was initially slow but steady and ultimately it surpassed the effect of standard drug which was initially very much prominent but sluggish later on. Likewise, an improvement of QOL by 50.43% and 41.17% in the test group and control group respectively has been observed. Although the effect of both the test drug and standard drug was found statistically significant (p<0.001) but the inter-group comparison revealed the test drug as highly significant (p<0.001) in comparison to the standard drug for improving the QOL of such patients. Interestingly, the patients having LUTS with BPH from the test group were more satisfied than those from control group at the end of the treatment.

The comparative effect of both the treatments on QOL is better depicted by the line graph in Figure 3. For the volume of prostate mean±SD in the test group was 34.73±15.02 before the onset and 29.64±13.01 after the accomplishment of the treatment period (Table 4). In the control group mean volume was 42.56±22.56 before onset and 42.23±22.50 after completion of the treatment. The change in prostate volume was not noticeable but compared to the control group, the improvement in the test group was statistically significant (p<0.001). Since the ingredients of the test drug formulation are concovive and purgative of phlegm (Mundij wa mushil-i-balgham), removes unwanted phlegm from the body and normalize the ratio of humors, a decrease in volume of the prostate to some extent was observed. The effect on PSA by both the test drug and standard drug was found to be statistically insignificant (Figure 4).\textsuperscript{14,27}

Furthermore, calculating the mean and standard error of mean of safety parameters before and after the treatment, both the drugs were found to be safe for such a period. Side effects such as dizziness, somnolence and decreased libido were reported in 8% of patients in control group and gastric upset complained in 3% of patients in the test group which is acceptable. Because almost all the ingredients of test drug are aphrodisiac, the side effects produced by the standard drug were not met with the test drug. Test drug formulation (Habb-i-muqil) overall produced the satisfactory results in our study.
Figure 2: Effect on AUA-SI in test and control group.

Figure 3: Effect on QOL in test and control group.

Figure 4: Effect on prostate volume and PSA in test and control group.
CONCLUSION

From this study, it was inferred that Habb-i-muqil was relatively effective in improving the overall AUA-SI and QOL compared to tamsulosin. No clinically significant adverse drug reaction was observed in the test group and overall compliance to the treatment was excellent. These results conclude that the test drug formulation is safe and effective in the management of symptomatic BPH. However, further study with larger sample size and with some additional parameters is required for elucidation.

ACKNOWLEDGEMENTS

This work was accomplished with special regards to Dr. Seema Akbar and whole team of RRIUM. The authors were also assisted by Dr. Adil Rashid and Abid Farooq in editing the article.

Funding: The financial support was provided by the Central Council for Research in Unani Medicine (CCRUM), an autonomous organization under the ministry of AYUSH, Government of India.

Conflict of interest: None declared

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Skinder D, Zacharia I, Studin J, Covino J. Benign prostatic hyperplasia: A clinical review. JAAPA. 2016;29(8):19-23.
2. Roehrborn CG, McConnell JD. In: Walsh P, Retik A, Vaughan E, Wein A, eds. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Campbell’s Urology. 8th ed. Philadelphia: Saunders; 2002. 1297-1336.
3. Kishorebabu A, Sree SN, Chandrakala SP. A review of benign prostatic hyperplasia. World J Current Med Pharm Res. 2019;1(5):192-7.
4. Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87-100.
5. Nunzio C, Presicce F, Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol. 2016;13(10):613-26.
6. Krušin B, Tomas D, Dzombeta T, Milkovic PM, Ulamec M. Inflammation in Prostatic Hyperplasia and Carcinoma-Basic Scientific Approach. Front. Oncol. 2017;7:77.
7. Vignera S, Condorelli RA, Russo GI, Morgia G, Calogero AE. Endocrine control of benign prostatic hyperplasia. Andrology. 2016;4(3):404-11.
8. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2013;189(1):102-6.
9. Bhat SA, Rather SA, Islam N. An overview of benign prostatic hyperplasia and its appreciation in Greco-Arab (Unani) system of medicine. Asian J Urol. 2021.
10. CCRUM. Kabiruddin M. Kitāb Al-Akhlāt. New Delhi; CCRUM; 2009: 79-85.
11. Dornbier R, Pahouia G, Branch J, McVary KT. The New American Urological Association Benign Prostatic Hyperplasia Clinical Guidelines: 2019 Update. Curr Urol Rep. 2020;21(9):32.
12. Gravas S, Corru JN, Gacci M, Gratzke C, Herrmann TRW, Mamoulaksis C, et al. Management of Non-neurogenic Male LUTS: EAU Guidelines. European Association of Urology. 2020.
13. Dong Z, Wang Z, Yang K, Liu Y, Gao W, Chen W. Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review. Syst Biol Reprod Med. 2009;55(4):129-36.
14. Kabir-ud-din M. Mahkazanul Mufradât. 3rd ed. New Delhi: Idara Kitāb-ul-Shifa; 2014: 50,95,96,225,261,355,356,388,389,415,416.
15. Antaki D. Tazkira ulul Alab wa Jami’ul Ajabul Ajab Part III. New Delhi: CCRUM; 2010: 48-49.
16. CCRUM. National Formulary of Unani Medicine Part I. New Delhi: CCRUM; 1993: 69.
17. Sarup P, Bala S, Kamboj S. Pharmacology and Phytochemistry of oleo-gum resin of conmiphora wightii (Guggulu). Scientific. 2015;5:1-14.
18. Bhat SA, Rather SA. Medicinal benefits and scientific justification of conmiphora mukul (muqil): a review. J Drug Delivery Therap. 2021;11(1):170-2.
19. Jain G, Das P. Guggulsterone: mechanism of action and prospects of chemoprevention in prostate cancer. Int J Pharm Sci Res. 2020;11(4):1527-36.
20. Bhat AA, Prabhu KS, Kuttikrishnann S, Krishnanukty R, Ramzi M. Potential therapeutic targets of guggulsterone in cancer. Nutr Metab. 2017;14:23.
21. Foster HE, Barry MJ, Gandhi MC, Kaplan SA, Kohler TS, Lerner LB, et al. Benign Prostatic Hyperplasia: Surgical Management of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms. American Urological Association, 2019. Available at: https://www.auanet.org/guidelines/benign-prostatic-hyperplasia-(bph)-guideline. Accessed on 15 July 2021.
22. Gnyawali D, Sharma U. Correlation of prostate volume with ‘International Prostate Symptom Score’ and ‘Benign Prostatic Hyperplasia-Impact Index’ in benign prostatic hyperplasia. J Societ Surg Nepal. 2014;17(1):6-9.
23. Tarique M, Ali T. A comparative study of efficacy and safety of a Unani formulation with the currently available drugs (Tamsulosin and Finasteride) in the management of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia. Int J Sci Res. 2020;9(1):66-7.
24. Vahlensiek W, Theurer C, Pfitzer E, Patz B, Banik N, Engelmann U. Effects of Pumpkin Seeds in men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia in the One-Year Randomized,
Placebo-Controlled GRANU Study. Urol Int. 2015;94:286-95.
25. Khan ZH, Akhtar MZ, Akhtar MW, Parveen S. Clinical study on haemorrhoids and therapeutic evaluation of habb-e-rasaaut and habb-e-muqil in its management. Hamdard Medicus. 2013;56(1):31-9.
26. Ansari A, Saleem S. Clinical efficacy of certain Unani treatment in the management of Waja-ur-Rukba (Knee-Osteoarthritis): a comparative observational study. J Biological Scientif Opinion. 2019;7(1):4-6.
27. Khare CP. Indian medicinal plants, An Illustrated Dictionary. New York, NY: Springer Science; 2007: 32,33,79,101,238,239,253,663,654.
28. Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019;65:458-64.
29. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: Results from the Baltimore Longitudinal Study of Aging. J Urol. 2009;182:1458-62.
30. Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: Prediction of future prostate volume in individual men. Prostate. 2007;67:1816-24.
31. Roehrborn CG, Wilson TH, Black LK. Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the combat trial. J Urol. 2012;187:1732-8.
32. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Corkery E, et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol. 1995;154(5):1770-4.

Cite this article as: Bhat SA, Rather SA, Islam N. Efficacy of a polyherbal formulation in the management of benign prostatic hyperplasia: a randomized, controlled trial. Int J Adv Med 2021;8:1387-94.